Related Experiment Videos
[Roxatidine acetate in therapy of reflux esophagitis]
P Friedrich1, R Botzler, R Mayershofer
1Städtisches Krankenhaus, Neustadt, Dresden.
Fortschritte Der Medizin
|June 10, 1996
Summary
Roxatidine acetate effectively treated gastro-oesophageal reflux disease, with symptom improvement in 90% of patients. Endoscopic healing rates varied by severity, and adverse events were minimal.
Area of Science:
- Gastroenterology
- Pharmacology
Context:
- Gastro-oesophageal reflux disease (GERD) affects a significant patient population.
- Effective and safe treatment options for GERD are crucial.
Purpose:
- To evaluate the efficacy and safety of roxatidine acetate in a large cohort of patients with GERD.
- To assess symptom improvement and endoscopic healing rates associated with roxatidine acetate treatment.
Summary:
- A study involving 3409 GERD patients treated with roxatidine acetate showed symptom improvement in approximately 90%.
- Endoscopic healing rates were observed in 1687 patients, with an overall rate of 65.3%.
- Healing rates decreased with increasing disease severity (Savary-Miller stages I-IV), ranging from 92.9% to 22.5%.
Impact:
- Roxatidine acetate demonstrates significant efficacy in managing GERD symptoms.
- The drug shows a considerable endoscopic healing potential, particularly in earlier disease stages.
- Adverse events were infrequent and generally minor, suggesting a favorable safety profile.